Immunocore Holdings (IMCR) Common Equity (2019 - 2026)

Immunocore Holdings has disclosed Common Equity across 8 years of filings, most recently posting $393.7 million for Q1 2026.

• Common Equity for Q1 2026 came in at $393.7 million, up 4.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $393.7 million (up 4.01% YoY), and the FY2025 annual result was $381.0 million, up 5.63% from the prior year.
• Common Equity came in at $393.7 million for Q1 2026 at Immunocore Holdings, up from $381.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $396.6 million in Q3 2025 to a low of $327.0 million in Q4 2022.
• The 5-year median for Common Equity is $364.8 million (2023), against an average of $367.1 million.
• Across the five-year window, Common Equity surged 41.39% in 2022 and declined 2.2% in 2024, its largest moves.
• Immunocore Holdings' Common Equity stood at $327.0 million in 2022, then grew by 12.81% to $368.8 million in 2023, then slipped by 2.2% to $360.7 million in 2024, then gained by 5.63% to $381.0 million in 2025, then increased by 3.32% to $393.7 million in 2026.
• The last three Common Equity figures came in at $393.7 million (Q1 2026), $381.0 million (Q4 2025), and $396.6 million (Q3 2025), per Business Quant data.